Business Wire

Blue Planet Prize 2025: Announcement of Prize Laureates

11.6.2025 05:00:00 EEST | Business Wire | Press release

Share

This year marks the 34th awarding of the Blue Planet Prize, the international environmental award sponsored by the Asahi Glass Foundation, chaired by Takuya Shimamura. Every year, the Foundation selects two laureates, individuals, or organizations who have made significant contributions to the resolution of global environmental problems. The Board of Directors has selected the following 2025 Blue Planet Prize laureates.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603602267/en/

Professor Robert B. Jackson (USA)

1. Professor Robert B. Jackson (USA) Born on September 26, 1961
Department of Earth System Science, Stanford University

Professor Robert B. Jackson is an expert on the carbon cycle in terrestrial ecosystems, including forests, grasslands, and wetlands. He has conducted pioneering research on the relationship between soil, vegetation, and soil bacterial communities. In addition, he has quantified the balance of greenhouse gases, such as carbon dioxide, methane, and nitrous oxide, from natural ecosystems and from fossil fuel use. Since 2017, he has served as chair of the Global Carbon Project (GCP), leading efforts to monitor and reduce greenhouse gas emissions.

2. Dr. Jeremy Leggett (UK) Born on March 16, 1954
Founder and CEO of Highlands Rewilding Ltd.
Inaugural chairman of the Carbon Tracker Initiative

Dr. Jeremy Leggett, as the inaugural chairman of the Carbon Tracker Initiative (CTI), introduced the concept of the "carbon bubble," highlighting the economic risks associated with fossil fuel assets. Through CTI’s activities, he influenced investors and policymakers, advancing the divestment movement. In addition, as a practical effort to balance economic activity with environmental conservation, he founded one of the UK’s leading solar energy companies. More recently, he has been spearheading initiatives in Scotland to connect ecological restoration with community prosperity.

  • Each laureate is presented with a certificate of merit, a commemorative trophy, and 500,000 US dollars in prize money.
  • The Award Ceremony is scheduled on Wednesday, October 29, 2025, at Tokyo Kaikan. Commemorative lectures will be given on October 30th and November 1st, 2025, at the University of Tokyo and at the Kyoto International Community House (kokoka), respectively.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250603602267/en/

Contacts

Toshihiro Tanuma, PhD
THE ASAHI GLASS FOUNDATION
2nd Floor, Science Plaza, 5-3 Yonbancho Chiyoda-ku, Tokyo 102-0081 Japan
Phone +81-3-5275-0620
e-mail: post@af-info.or.jp
URL: https://www.af-info.or.jp/en/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.af-info.or
.jp%2Fen%2F&esheet=54264919&newsitemid=20250603602267&lan=en-US&anchor=https%3A%
2F%2Fwww.af-info.or.jp%2Fen%2F&index=1&md5=9e29736729569b4f682b605661e41837

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 02:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen. According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances. IDE034 is a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and lice

IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p

HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release

HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C

Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 10:15:00 EET | Press release

Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char

DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 09:18:00 EET | Press release

Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers compared to currently available technologies. This in turn is boosting expectations

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye